

The logo for Menicon BLOOM. The word "Menicon" is in a smaller, white, sans-serif font above the word "BLOOM". "BLOOM" is in a larger, white, bold, sans-serif font. A trademark symbol (TM) is located to the upper right of the "M" in "BLOOM". The background of the logo area is a dark blue to purple gradient with a starry, nebula-like texture.

Menicon
BLOOMTM


White paper on
Menicon BloomTM
Myopia Control Management System

September 2025

Disclaimer


This white paper contains proprietary information from Menicon Co., Ltd. on 'Menicon Bloom Myopia Control Management System'. Neither Menicon Co., Ltd. nor any person acting on the company's behalf may be held responsible for the use which may be made of the information contained herein. If you require further information or have received this document in error, please notify Menicon Co., Ltd. Thank you for your understanding.

www.menicon.com



Contents

Introduction	4
What Is Myopia?	4
What Causes Myopia?	5
Pathology of Myopia	5
The Health & Social Impacts of Myopia	6
Mitigating the Risks Associated With Increased Levels of Myopia	6
How Can Myopia Be Detected and Controlled?	7
Menicon Bloom Myopia Control Management System – How Does It Work?	7
Is Menicon Bloom Efficacious, Safe & Acceptable?	9
Choosing the Right Treatment for Your Patient	11
How & Who Can Prescribe Menicon Bloom?	12
Why CE Approval Matters	12
Reference	13



Introduction

The prevalence of myopia has increased in recent decades to affect approximately 30% of the world's population and it has been estimated to significantly increase to affect about 50% of the world's population by 2050 (**Figure 1**).¹ Of particular concern is that even relatively low degrees of myopia may be associated with an increased risk of sight-threatening ocular complications, with the risk increasing substantially with higher levels of myopia.²⁻⁸ Concerned with the growing incidence of myopia and its health consequences worldwide, Menicon Co., Ltd. has dedicated significant resources to develop **Menicon Bloom Myopia Control Management System**, a holistic approach for myopia control management. The system offers two contact lens types for myopia management: **Menicon Bloom Day™**, a center-distance extended depth of focus daily disposable soft contact lens with CE-approval specifically for Myopia progression control, and **Menicon Bloom Night™**, the first CE- approved orthokeratology contact lens for myopia control management in Europe. Accompanying these contact lens products are lens care solutions (i.e., **Menicon Bloom Care and Menicon Bloom Progent**) to ensure optimal hygiene and safety for **Menicon Bloom Night™** lens wear. Additionally, this system includes digital tools (**Menicon Bloom Easyfit and Menicon Bloom app**) to help with the lens fitting and to enhance communications between the patient and the eye care professional for closer tracking of each individual myopia control journey, respectively. Menicon was the first company in the world to offer both soft and orthokeratology contact lens devices specifically approved for myopia control in Europe within the context of a comprehensive treatment system. The rationale for the launch and the details of this myopia control management system are explained in this white paper.




Figure 1. Graph showing the estimated prevalence of myopia (spherical equivalent refractive error ≤ -0.50 D when ocular accommodation is relaxed) and high myopia (spherical equivalent refractive error ≤ -6.00 D when ocular accommodation is relaxed) for each decade from 2000 through 2050. Data replotted from Holden et al.¹

What Is Myopia?

Our understanding of myopia has increased substantially with the publication of a number of white papers providing global consensus on different aspects related to myopia in 2019⁹⁻¹⁵ and more recent updates in 2021.^{13,16-21} The International Myopia Institute has defined myopia, also known as near- or short-sightedness, as a 'refractive error in which rays of light entering the eye parallel to the optic axis are brought to a focus in front of the retina when ocular accommodation is relaxed. This usually results from the eyeball being too long from front to back, but can be caused by an overly curved cornea and/or a lens with increased optical power' (Figure 2).⁹ Myopia typically causes blurred distance vision while objects at near may appear clear. It normally develops during childhood and progresses until the mid to late teenage years, with younger children and females showing greater annual rates of myopia progression.^{22,23}

Myopia is one of the most common refractive errors and a major cause of vision impairment worldwide.^{1,24} The prevalence of myopia in young adolescents has been increasing in recent decades to about 30% in industrialized societies of the West and epidemic levels of over 90% in some parts of Far East Asia.^{1,25-30} Globally, it is recognized as a significant public health concern associated with increased ocular-related morbidity, considerable healthcare costs, indirect costs such as lost productivity and reduced quality of life.^{2,8,9,24,31-34}

Of particular concern is the association of increasing levels of myopia with a higher risk of potentially blinding ocular pathologies such as glaucoma, myopic maculopathy, and vitreous and retinal detachments.²⁻⁸ Furthermore, high myopia has also been found to contribute to a general degradation of quality of life due to psychological, cosmetic and practical reasons.³⁵




Figure 2. The image on the left shows the refractive status of an emmetropic eye where light rays entering the eye focus on the retina, whereas the image on the right represents a myopic eye where light rays entering the eye focus in front of the retina causing blurred distance vision.

What Causes Myopia?

The underlying cause behind the onset and progression of myopia is believed to be a combination of genetic and environmental factors.¹¹ Risk factors include ethnicity, number of myopic parents, time engaged in close work, lack of time spent outdoors, and country and location (i.e., urban/rural) of residency.^{10,20,36-43}

Pathology of Myopia

Traditionally, myopia has been broadly perceived, apart from a very small minority of high myopes, as simply an optically correctable inconvenience.⁴⁴ However, the perception that ‘physiological myopia’ as just an ‘optical inconvenience’ has changed over the last two decades as increasing scientific evidence has established a clear link between increasing levels of myopia and an increased risk of a wide range of ocular pathologies, with even low levels of myopia carrying an increased risk of potentially blinding ocular complications.^{2-8,45} Pathologic myopia is a major cause of irreversible visual impairment worldwide⁴⁶⁻⁵⁰ and conditions such as myopic maculopathy and high myopia-associated optic neuropathy are already among the most frequent causes of irreversible vision loss and blindness in East Asia.⁵¹⁻⁵³ A recent systematic review and meta-analysis of studies determined that low, moderate, and high myopia were all associated with increased risks of myopic macular degeneration (MMD), retinal detachment (RD), posterior subcapsular cataract (PSC), nuclear cataract (NC), open angle glaucoma (OAG), and blindness.⁴⁵ The risk of visual impairment was strongly related to longer axial length, higher degree of myopia, and age older than 60 years (**Table 1**). Although high myopia carries the highest risk of complications and visual impairment, low and moderate myopia also have considerable risks (**Table 1**). These estimates should alert policy makers and health care professionals to make myopia a priority for prevention and treatment.

		Degree of Myopia		
		Low	Moderate	High
Ocular complication	MMD	13.57 [6.18–29.79]	72.74 [33.18–159.48]	845.08 [230.05–3104.34]
	RD	3.15 [1.92–5.17]	8.74 [7.28–10.50]	12.62 [6.65–23.94]
	PSC	1.56 [1.32–1.84]	2.55 [1.98–3.28]	4.55 [2.66–7.75]
	NC	1.79 [1.08–2.97]	2.39 [1.03–5.55]	2.87 [1.43–5.73]
	OAG	1.59 [1.33–1.91]	2.92 [1.89–4.52]	2.92 [1.89–4.52]
	Blindness	1.71 [1.07–2.74]	5.54 [3.12–9.85]	87.63 [34.50–222.58]

Table 1. Summary of the results of a systematic review and meta-analysis that determined the risk between degree of myopia, assessed in terms of spherical equivalent refractive error (SER), and myopic macular degeneration (MMD), retinal detachment (RD), posterior subcapsular cataract (PSC), nuclear cataract (NC), open angle glaucoma (OAG), and blindness. Low myopia (i.e., SER < -0.5 to > -3.00 D), moderate myopia (i.e., SER ≤ -3.00 to > -6.00 D), high myopia (i.e., ≤ -6.00 D). Risks are reported in terms of odds ratios [95% confidence intervals]. The risks for blindness are reported in participants aged >60 years. Data drawn from Haarman et al. 2020.⁴⁵

The Health & Social Impacts of Myopia

Globally, uncorrected refractive errors represent a major cause of vision loss, particularly in developing countries, and refractive errors have been listed as one of the five priority conditions in the World Health Organizations 'Vision 2020'.⁵⁴ Myopia has a tremendous impact on individuals and society due to its lifetime of direct health expenditure, potential pathological manifestations and indirect costs such as lost productivity and reduced quality of life,³⁴ even in developed countries where the majority of myopes have normal visual acuity with the appropriate optical correction.²


The prevalence of myopia is high and rising worldwide with consequences spanning from childhood to late adult life. Recent evidence reveals that the prevalence of high myopia is growing at a faster rate than the prevalence of overall myopia.³⁴ This is in conjunction with rising rates of serious blinding complications associated with high myopia, notably myopic macular degeneration. Myopic maculopathy, a condition associated with significant risks of visual loss² and measurable reductions in quality of life,⁵⁵ is the most obvious link between myopia and ocular pathology. Quality of life is adversely affected by uncorrected myopia, high myopia, and complications of high myopia,^{35,56} with high levels of myopia being associated with an impact on quality of life comparable with keratoconus.³⁵

Currently, the global costs related to direct health expenditure and lost productivity as a result of myopia are in the range of several hundred billion dollars annually.³⁴ Unless the current trajectory for the rising prevalence of myopia and high myopia is lowered, the costs will continue to grow.

Mitigating the Risks Associated With Increased Levels of Myopia

Population growth and ageing, along with urbanization, behavioural and lifestyle changes, is expected to dramatically increase the number of people with eye conditions, vision impairment and blindness in the coming decades.⁵⁷ Given the clear link between increasing levels of myopia as a result of an elongation of the eye and the increased risks of developing ocular pathology in the ageing eye, strategies aimed at reducing myopia and the axial elongation of the eye are likely to reduce the risk of suffering from a wide range of sight-threatening complications (**Table 1**).^{17,45} Studies have estimated that the benefits of reducing the axial elongation of the eye of myopic pediatric patients as a result of contact lens wear outweigh the risks associated with the wear of contact lenses.^{46,58} It has been recently estimated that between 4 and 7 patients with a mean age of 12 years need to receive myopia control treatment with contact lenses to prevent 5 years of visual impairment (assuming a mean life expectancy of 82 years), while fewer than 1 in 38 will experience a loss of vision as a result of suffering from microbial keratitis due to myopia control contact lens wear.⁴⁶ Measurement of myopia progression, especially axial elongation, is key to assessing the effectiveness of strategies aimed at reducing eye growth and, in turn, the potential to mitigate the risk of future ocular pathology in the aging eye. It has been reported that the greatest impact on eye growth and myopia progression occurs when treatment is started early and sustained over a longer period. Early intervention provides an opportunity to accumulate treatment effects over more years during which the eye would be growing, resulting in a greater total treatment benefit.⁴⁷

Shifting the trajectory of myopia requires a coordinated global effort and success has already been demonstrated with some optical, environmental, and pharmaceutical strategies to prevent the onset and/or effectively slow the progression of myopia.³⁴ An early and appropriate intervention mitigates the risks and consequences related to uncorrected vision. More importantly, it can reduce the risk of the eye progressing to higher levels of myopia and have a positive impact on reducing the public health burden.



How Can Myopia Be Detected and Controlled?


Qualified eye care professionals can diagnose myopia through an eye examination. Myopia has historically been managed via correction of the refractive error with optical interventions. Spectacles are the easiest and most popular method of correcting refractive myopia followed by contact lenses.⁴⁸⁻⁵⁰ Refractive surgery, which permanently changes the shape of the cornea, is usually indicated in early adulthood for patients with stable and relatively low myopia. Whilst all these strategies employ optical mechanisms designed to correct a patient's refractive state by focusing light on the retina to improve distance vision, these remedies are not intended to control myopia progression. On the contrary, in some cases these optical devices may exacerbate the progression of myopia.^{10,15,59} There is evidence indicating myopia can be mitigated by having children spend more time outdoors and through the use of specialized optical devices and medicines.^{10,15} There is strong scientific evidence from case reports, retrospective studies, prospective clinical trials, systematic reviews and meta-analyses that center-distance multifocal soft contact lens wear and overnight orthokeratology contact lens wear are effective treatment options for myopia control in children and young adults.^{10,15,59-62} Currently, there are several treatment options that have official regulatory approval for myopia control.¹⁴

Menicon Bloom Myopia Control Management System – How Does It Work?

The **Menicon Bloom Myopia Control Management System** was carefully developed to provide eye care professionals worldwide with a variety of high quality, officially approved (i.e., on-label) treatment options to address the myopia epidemic. This myopia control management system not only encompasses both soft and orthokeratology contact lens devices, which can be conveniently worn either during the day or night (**Menicon Bloom Day™** and **Menicon Bloom Night™**, respectively), but also digital tools for professionals and patients (**Menicon Bloom Easyfit** and **Menicon Bloom app**) to support both parties and to consider communication between them as a key factor to success with a long-term myopia control treatment.

Menicon Bloom Easyfit is Menicon's user-friendly, cloud-based, lens fitting and tracking tool for eye care professionals. It facilitates the collection of the patient's myopia-related information and the calculation of the most suitable **Menicon Bloom** lens for each individual eye. It offers two different paths for fitting: the Guided and the Quick Workflows. The different workflows displayed in the Guided mode include each patient visit, guide the eye care professional through the examination process and help to ensure the most important clinical information is evaluated at each visit. The treatment history is retained and maintained in the software for easy continuity of treatment. The software also includes a myopia tracking feature that helps the professional effectively track and manage the outcome of their patient's treatment with both **Menicon Bloom Night™** and **Menicon Bloom Day™**.

The **Menicon Bloom app** is a unique, intuitive mobile phone application for patients. It has been created specifically to enhance communication between the patient and eye care professional. It was designed to help support and guide patients through their myopia journey. The **Menicon Bloom app** helps foster the correct behavioral patterns related to compliance by asking patients about their experiences with the lenses and providing tips for improvement. Eye care professionals can check their patients' responses to the **Menicon Bloom app** on **Menicon Bloom Easyfit** so they can be alerted with regards to any issues the patient may be facing prior to their next appointment. **The Menicon Bloom app** can also be used to facilitate direct communications between the patient and eye care professional or practice to help address any questions and concerns the patient may have. In addition, it provides continuous access to lens handling and maintenance instructions.



With its **Neurofocus Optics**[®] technology, **Menicon Bloom Day**[™] uses a catenary-curve-like power profile lens design, which provides a rapidly and smoothly increase in lens power up to +8D, resulting in a wide spread of myopic defocus over an area of more than 30 degrees on the peripheral retina whilst simultaneously providing clear vision along the visual axis.^{63,64}




Figure 3. Menicon Bloom Day power profile map. Power changes along the horizontal axis of the Menicon Bloom Day myopia progression control contact lens. Positive (up to +5mm) and negative (up to -5mm) values represent changes in lens power towards the nasal and temporal directions, respectively, 0 represents the geometrical center of the lens.

Menicon Bloom Night[™] therapy involves the overnight wear of a specially designed orthokeratology contact lens manufactured in hyper-oxygen permeable Menicon Z material, which has consistently exhibited oxygen permeability levels of over 180 Fatt units,⁶⁵ thus being the gas permeable contact lens material with the highest oxygen permeability in the world, consequently ensuring the highest corneal oxygenation for comfortable and safe contact lens wear.⁶⁶⁻⁷⁰ Menicon Z Material brings wearers a lot of benefits in terms of safety, but to minimise adverse events or lens surface changes, the recommendation is to replace the lens every 6 months.⁷¹ Additionally, patients undergoing myopia control treatment should be assessed at least every 6 months to monitor the safety and efficacy of the treatment.^{10,71}

The treatment temporarily changes the shape of the cornea by flattening and steepening the central and mid-peripheral corneal curvatures, respectively. These corneal changes occur overnight and reduce refractive error, thus eliminating the need to wear contact lenses throughout the waking hours after lenses are removed.⁷² The new corneal shape provides a particular optical path for incoming light that counters the ocular growth response associated with myopia development (**Figure 4**).⁶⁰ Studies conducted with **Menicon Bloom Night**[™] lenses have found significant changes in high-order ocular aberrations,^{73,74} with the increase in positive spherical aberration induced by the wear of these lenses⁷⁵ presumably being responsible for its well-established effectiveness in reducing the axial elongation of the eye.⁷⁶⁻⁷⁸ Through this mechanism, **Menicon Bloom Night**[™] is indicated for the correction of refractive myopia and for control of myopia when prescribed and managed by a qualified eye care professional. **Menicon Bloom Night**[™] myopia control therapy is currently available in two different contact lens designs: **Menicon Bloom Night**[™] and **Menicon Bloom Night**[™] Toric. Both lens designs can correct up to -6.00D of myopia, with **Menicon Bloom Night**[™] Toric providing additional options for eyes with higher corneal astigmatism levels.





Figure 4. Menicon Bloom Night innovative orthokeratology contact lens design for myopia control fitted on an eye. Upon lens removal, the treatment provides a new corneal shape that counters the ocular growth response associated with myopia development.



The recommended care solutions for **Menicon Bloom Night™** contact lenses are **Menicon Bloom Care** and **Menicon Bloom Progent**. **Menicon Bloom Care** is a multipurpose solution with a demonstrated wide spectrum of disinfection against pathogenic microorganisms.^{79–81} The solution comes in a unique bottle shape and material for improved handling by children. **Menicon Bloom Care** is also manufactured with significantly less plastic consistent with Menicon’s commitment towards sustainable development goals (<https://www.menicon.com/corporate/sdg/>). Additionally, to ensure safe and comfortable lens wear the use of **Menicon Bloom Progent**, an outstanding protein remover, disinfectant and intensive cleaner,⁸² is recommended in combination with **Menicon Bloom Care**.

Is Menicon Bloom Efficacious, Safe & Acceptable?

Comprehensive scientific evidence collected over the years has supported the efficacy, safety and acceptance of **Menicon Bloom Day™** and **Menicon Bloom Night™** as successful treatment options for myopia control management. The latter has been independently confirmed by notified bodies in Europe ultimately granting the treatments CE-approval for the specific indication of myopia control.


Efficacy

A retrospective case series analysis from 10 practice locations in the US, which analyzed data from 32 patients (ages 6–19 years), has shown **Menicon Bloom Day™** substantially slows myopia progression in children.⁸³ A follow-up retrospective analysis involving 15 practice locations in the US, which analyzed data from 192 patients who wore **Menicon Bloom Day™** lenses for about 6 years, further supported the efficacy of this unique myopia control lens in slowing myopia progression.⁸⁴ Additionally, this unique extended depth of focus contact lens has also shown to correct peripheral hyperopia, the putative stimulus responsible for myopia progression,⁶³ and improve amplitude and lag of accommodation by 1.00D and 0.50D, respectively.⁸⁵

The 1-year results of an ongoing, multinational, double-masked, randomized, controlled trial conducted with the **Menicon Bloom Day™** have shown the lens to be very effective in slowing myopia progression in children. After 1-year follow-up, the Menicon Bloom Day™ group showed a reduction in myopia progression and axial elongation versus the control group of 0.41D or 71% and 0.17 mm or 61%, respectively. Sixty-four percentage of subjects showed no meaningful progression (0.25D or less).⁸⁶ In conjunction with previous six-year data⁸⁷ and two additional independent studies,^{88,89} these results further support **Menicon Bloom Day™** as a safe and effective treatment for slowing myopia progression in children.

Recently released, 2-year data⁹⁰ underscore the safety and efficacy of Menicon Bloom Day™ in managing myopia progression in children. Results demonstrate a significant reduction in refractive error and axial elongation compared to the control group. The adjusted treatment effect at two years on refractive error progression was 0.59 D, a 56% reduction compared to the control group. The adjusted treatment effect at two years on axial elongation was 0.22 mm, a 46% reduction compared to the control group.

An independent clinical trial validated **Menicon Bloom Day™** lens astigmatism correction indication of up to 2.00 D. Menicon Bloom Day™ can correct an extensive range of astigmatism by enabling both meridians to focus simultaneously due to its patented extended depth of focus design, efficacy to correct 100% astigmatism at 2.00 D and 83% at 3.00.⁹¹




Several peer-reviewed studies specifically conducted with **Menicon Bloom Night™** for myopia control treatment have demonstrated significant levels of efficacy,^{76–78} even following long periods of contact lens wear.⁹² A more recent peer-review publication provides further insights into the well-established efficacy of **Menicon Bloom Night™** lenses for slowing myopia progression in children.¹²⁹ More specifically, the latter study found that the use of **Menicon Bloom Night™** lenses provides a mean 2-years reduction in the axial elongation of the eye of 0.24mm in comparison to distance, single-vision spectacle lens wear, with over 60% of the treatment effect being obtained during the first year of treatment. The myopia control efficacy of **Menicon Bloom Night™** lenses was found to be independent of the patient's age, gender, baseline refractive error and ethnicity indicating that their use provide similar levels of effectiveness in slowing myopia progression regardless of these factors. Finally, the study found that while **Menicon Bloom Night™** lenses can successfully correct refractive error in most subjects (within the indications for use of the device), these lenses were also effective in slowing myopia progression in 75% of lens wearers.

Safety

Like any other treatment, contact lens wear can be associated with the development of adverse events and complications. However, recent large studies, including systematic reviews and meta-analyses, have demonstrated **Menicon Bloom Day™** and **Menicon Bloom Night™** type contact lenses, if fitted correctly by an eye care professional according to the manufacturer's instructions, are safe to use in pediatric populations.^{93–97}

A review of nine prospective studies specifically conducted in children 7 to 19 years old wearing soft contact lenses, which collectively represents 1800 patient years of wear, reported the incidence of corneal infiltrative events in children to be no higher than that found in adults. The incidence was found to be markedly lower in the youngest age range of 8 to 11 years in comparison with adults.⁹⁶ A more recent data analysis from six randomized myopia control trials conducted with daily disposable hydrogel (i.e., etafilcon A) contact lenses in 581 myopic children (aged 7 to 15 years at baseline) reported no significant or serious ocular adverse events, including corneal infections or serious corneal infiltrative events indicating daily disposable etafilcon A hydrogel contact lenses are safe for use in children.⁹⁷ All together, these results support the safety of **Menicon Bloom Day™** daily disposable soft contact lenses for the purposes of myopia progression control in children.

Specific studies performed with **Menicon Bloom Night™** for myopia control management have shown that the complications associated with the use of the device are typically not considered to be serious; are similar to those reported with other contact lens types; and can be managed straightforwardly in clinical practice.^{76,78,98} A more recent peer-review publication further reaffirms the safety of **Menicon Bloom Night™** lenses for slowing myopia progression in children.¹³⁰ Additionally, post-marketing surveillance and complaint trend data from the manufacturer as well as potential adverse events reported with **Menicon Bloom Night™** orthokeratology contact lenses in external databases have been reviewed. Analysis of all this data has provided conclusive evidence supporting **Menicon Bloom Night™** as a safe, viable myopia control treatment option.⁹⁹



Acceptance

The fitting of contact lenses on children and young adolescents has received resistance by eye care professionals worldwide over the years. This is likely related to perceptions related to decreased capacity for minors to care for contact lenses, more fitting and training time, and inferior risk-to-benefit ratio compared to adults. The latter might explain why children and teenagers with refractive errors have traditionally been corrected with spectacles, despite reports of successful contact lens wear in minors with different types of contact lenses, including soft, rigid gas-permeable and orthokeratology contact lenses.^{100–106} More specifically, many studies have shown that minors are fully capable of using and caring for soft and orthokeratology contact lenses.^{76,77,92,103,107–112} Studies have also shown that certain soft and orthokeratology contact lenses are becoming popular forms of optical correction and myopia control management for children and young adolescents.^{48,49,113,114} The use of contact lenses has been found to dramatically improve how children and teenagers feel about their appearance and participation in activities, leading to greater satisfaction with their refractive error correction.^{102,106}


Menicon Bloom Day[™] has been shown to perform comparably to a single vision spherical lens by providing excellent distance, intermediate and near vision at high and low contrasts, with subjective overall vision rated remarkably high.⁸⁵ Additionally, **Menicon Bloom Day[™]** provided stereoacuity identical to that found with the spherical soft contact lens and a slight improvement in reading rates for smaller text.⁸⁵ Similarly, **Menicon Bloom Night[™]** therapy has shown to be well-accepted by parents and to improve children's overall vision, far distance vision, symptoms, appearance, satisfaction, activities, academic performance, handling and peer perceptions in comparison to single vision spectacle lens wear.¹¹⁵

Collectively, the above studies indicate that the benefits of prescribing **Menicon Bloom Myopia Control Management System** to children with progressive myopia would outweigh the potential risks associated with the treatment. **Menicon Bloom Day[™]** and **Menicon Bloom Night[™]** have met the highest standards of safety, efficacy and quality required to grant the treatments CE approval for myopia progression control management in Europe. As such, if used correctly in accordance with the instructions for use, **Menicon Bloom Day[™]** and **Menicon Bloom Night[™]** provide excellent benefits for myopia control with very limited risks in children.^{46,58}

Choosing the Right Treatment for Your Patient

In implementing a myopia management strategy, it is important to choose the right treatment type for your patient while also considering the best time to start and stop treatment. Research indicates that lower levels of hypermetropia at a young age is a strong risk factor for future myopia development.^{116,117} Furthermore, the major factor contributing to faster myopia progression is younger age at myopia onset, with this factor being independent of gender, ethnicity, school, time spent reading and parental myopia.¹⁰ Myopia progresses at much faster rates in children compared to teenagers, with faster progression rates typically being observed in children between 7 to 12 years of age,¹¹⁸ thus supporting the need for earlier intervention with **Menicon Bloom Myopia Control Management System** in myopic children.²³ To maximize the myopia control effect and minimize potential rebound effects,¹¹⁹ eye care professionals are recommended to continue myopia control treatment until myopia progression stabilizes, which has been reported to occur sometime between 16 to 21 years of age in early-onset myopes.²³

Certified eye care professionals on **Menicon Bloom Myopia Control Management System** can conveniently choose between **Menicon Bloom Day[™]** and **Menicon Bloom Night[™]** for myopia control management depending on the child's refractive and biometric status as well as on visual, handling and lifestyle demands.



How & Who Can Prescribe Menicon Bloom?

Menicon Bloom Day™ features one universal, easy-to-fit lens design for optimal fit efficiency that provides an 88% initial on-eye fitting success rate.¹²⁰ The fitting of **Menicon Bloom Night™** is optimized by the use of a corneal topographer in conjunction with **Menicon Bloom Easyfit** software and it has demonstrated a 90% first fit success rate in children.¹²¹ Additionally, **Menicon Bloom app** has been developed to enhance the tracking and communication process between eye care professionals and patients.

Menicon Bloom Myopia Control Management System is only available for certified eye care professionals.


Why CE Approval Matters

Marketing a medical device in Europe requires a marketing authorization ('product license') for specified indications under specified conditions (e.g., target population, indication, specific use), regulated by the country's medicines and health care products regulatory agency.^{122,123} This process is employed to ensure that medical products meet the required standards of safety, efficacy and quality before being issued a marketing authorization, which allows the medical device to become available to the general public. In Europe, products that hold a marketing authorization are designated a 'CE' marking. Prescribing a licensed product outside the approved scope of use is called 'off-label' prescribing. An example of off-label prescribing occurs when a regular soft multifocal contact lens, which has an indication for vision correction for patients >40 years who experience reading difficulties, is fitted for myopia control purposes to a child where both the indication (i.e., reading difficulties vs. reducing myopia progression) and target group (i.e., adults vs. children) are different from those for which the product has been approved for. Similarly, off-label prescribing also occurs when an orthokeratology contact lens, which is approved for the correction of manifest myopia in adults, is prescribed for reducing myopia progression in children, where again both the indication (i.e., correcting manifest myopia vs. reducing myopia progression) and target group (i.e., adults vs. children) are different from those for which the product has been approved for. When prescribing a treatment for myopia control, the eye care professional should ideally start by considering all on-label products that may be available and only contemplate off-label prescribing if there are no on-label options or if approved products are not effective or appropriate.¹⁴ In off-label prescribing, the patient must be adequately informed about the lack of product authorization and the possible existence of unknown risks.¹²⁴⁻¹²⁸ Parents and legal guardians should be informed of all options and associated risks in order to decide whether the child should be treated with a tested and approved on-label treatment or with an off-label treatment that might give a successful result, but has unknown risks.

With the official marketing authorization for myopia control management, the contact lenses included in Menicon

Bloom Myopia Control Management System, **Menicon Bloom Day™** and **Menicon Bloom Night™**, have met the required standards of safety, efficacy and quality required to grant the treatment CE approval for myopia control management in Europe. With such approval, eye care professionals can now have peace of mind with the on-label prescription of this myopia control therapy.

* Menicon Bloom, Menicon Bloom Day, Menicon Bloom Night, Menicon Bloom Care, Menicon Bloom Progent, Menicon Z and Easyfit are trademarks of Menicon Co., Ltd



Reference

1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. *Ophthalmology*. 2016;123(5):1036-1042. doi:10.1016/j.ophtha.2016.01.006
2. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. *Prog Retin Eye Res*. 2012;31(6):622-660. doi:10.1016/j.preteyeres.2012.06.004
3. Tano Y. Pathologic myopia: where are we now? Internet Advance publication at ajo.com Sept 17, 2002. *Am J Ophthalmol*. 2002;134(5):645-660. doi:10.1016/S0002-9394(02)01883-4
4. Vongphanit J, Mitchell P, Wang JJ. Prevalence and progression of myopic retinopathy in an older population. *Ophthalmology*. 2002;109(4):704-711. doi:10.1016/S0161-6420(01)01024-7
5. Wong TY, Klein BEK, Klein R, Knudtson M, Lee KE. Refractive errors, intraocular pressure, and glaucoma in a white population. The authors have no proprietary interest in the products or devices mentioned herein. *Ophthalmology*. 2003;110(1):211-217. doi:10.1016/S0161-6420(02)01260-5
6. Saw S, Gazzard G, Shih-Yen EC, Chua W. Myopia and associated pathological complications. *Ophthalmic and Physiological Optics*. 2005;25(5):381-391. doi:10.1111/j.1475-1313.2005.00298.x
7. Ikuno Y, Jo Y, Hamasaki T, Tano Y. Ocular Risk Factors for Choroidal Neovascularization in Pathologic Myopia. *Investigative Ophthalmology & Visual Science*. 2010;51(7):3721. doi:10.1167/iops.09-3493
8. Tideman JW, Snabel MCC, Tedja MS, et al. Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia. *JAMA Ophthalmol*. 2016;134(12):1355. doi:10.1001/jamaophthalmol.2016.4009
9. Flitcroft DI, He M, Jonas JB, et al. IMI – Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. *Invest Ophthalmol Vis Sci*. 2019;60(3):M20. doi:10.1167/iops.18-25957
10. Gifford KL, Richdale K, Kang P, et al. IMI – Clinical Management Guidelines Report. *Invest Ophthalmol Vis Sci*. 2019;60(3):M184-M203. doi:10.1167/iops.18-25977
11. Tedja MS, Haarman AEG, Meester-Smoor MA, et al. IMI – Myopia Genetics Report. *Investigative Ophthalmology & Visual Science*. 2019;60(3):M89. doi:10.1167/iops.18-25965
12. Troilo D, Smith EL, Nickla DL, et al. IMI – Report on Experimental Models of Emmetropization and Myopia. *Investigative Ophthalmology & Visual Science*. 2019;60(3):M31. doi:10.1167/iops.18-25967
13. Wolffsohn JS, Kollbaum PS, Berntsen DA, et al. IMI – Clinical Myopia Control Trials and Instrumentation Report. *Investigative Ophthalmology & Visual Science*. 2019;60(3):M132. doi:10.1167/iops.18-25955
14. Jones L, Drobe B, González-Méijome JM, et al. IMI – Industry Guidelines and Ethical Considerations for Myopia Control Report. *Investigative Ophthalmology & Visual Science*. 2019;60(3):M161. doi:10.1167/iops.18-25963
15. Wildsoet CF, Chia A, Cho P, et al. IMI – Interventions for Controlling Myopia Onset and Progression Report. *Investigative Ophthalmology & Visual Science*. 2019;60(3):M106. doi:10.1167/iops.18-25958
16. Wolffsohn JS, Jong M, Smith EL, et al. IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice. *Investigative Ophthalmology & Visual Science*. 2021;62(5):1. doi:10.1167/iops.62.5.1
17. Jonas JB, Ang M, Cho P, et al. IMI Prevention of Myopia and Its Progression. *Investigative Ophthalmology & Visual Science*. 2021;62(5):6. doi:10.1167/iops.62.5.6
18. Jong M, Jonas JB, Wolffsohn JS, et al. IMI 2021 Yearly Digest. *Investigative Ophthalmology & Visual Science*. 2021;62(5):7. doi:10.1167/iops.62.5.7
19. Logan NS, Radhakrishnan H, Cruickshank FE, et al. IMI Accommodation and Binocular Vision in Myopia Development and Progression. *Investigative Ophthalmology & Visual Science*. 2021;62(5):4. doi:10.1167/iops.62.5.4
20. Morgan IG, Wu PC, Ostrin LA, et al. IMI Risk Factors for Myopia. *Investigative Ophthalmology & Visual Science*. 2021;62(5):3. doi:10.1167/iops.62.5.3

21. Ohno-Matsui K, Wu PC, Yamashiro K, et al. IMI Pathologic Myopia. *Investigative Ophthalmology & Visual Science*. 2021;62(5):5. doi:10.1167/iovs.62.5.5
22. GOSS DA, WINKLER RL. Progression of Myopia in Youth. *Optometry and Vision Science*. 1983;60(8):651-658. doi:10.1097/00006324-198308000-00002
23. COMET Group. Myopia stabilization and associated factors among participants in the Correction of Myopia Evaluation Trial (COMET). *Invest Ophthalmol Vis Sci*. 2013;54(13):7871-7884. doi:10.1167/iovs.13-12403
24. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. *Lancet Glob Health*. 2017;5(12):e1221-e1234. doi:10.1016/S2214-109X(17)30393-5
25. Pan CW, Dirani M, Cheng CY, Wong TY, Saw SM. The Age-Specific Prevalence of Myopia in Asia. *Optometry and Vision Science*. 2015;92(3):258-266. doi:10.1097/OPX.0000000000000516
26. Koh V, Yang A, Saw SM, et al. Differences in Prevalence of Refractive Errors in Young Asian Males in Singapore between 1996–1997 and 2009–2010. *Ophthalmic Epidemiol*. 2014;21(4):247-255. doi:10.3109/09286586.2014.928824
27. Pan C, Ramamurthy D, Saw S. Worldwide prevalence and risk factors for myopia. *Ophthalmic and Physiological Optics*. 2012;32(1):3-16. doi:10.1111/j.1475-1313.2011.00884.x
28. Wang TJ, Chiang TH, Wang TH, Lin LLK, Shih YF. Changes of the ocular refraction among freshmen in National Taiwan University between 1988 and 2005. *Eye*. 2009;23(5):1168-1169. doi:10.1038/eye.2008.184
29. Vitale S. Increased Prevalence of Myopia in the United States Between 1971-1972 and 1999-2004. *Archives of Ophthalmology*. 2009;127(12):1632. doi:10.1001/archophthalmol.2009.303
30. Gilmartin B. Myopia: precedents for research in the twenty-first century. *Clin Exp Ophthalmol*. 2004;32(3):305-324. doi:10.1111/j.1442-9071.2004.00831.x
31. Vitale S, Cotch MF, Sperduto R, Ellwein L. Costs of Refractive Correction of Distance Vision Impairment in the United States, 1999–2002. *Ophthalmology*. 2006;113(12):2163-2170. doi:10.1016/j.ophtha.2006.06.033
32. Lim MCC, Gazzard G, Sim EL, Tong L, Saw SM. Direct costs of myopia in Singapore. *Eye*. 2009;23(5):1086-1089. doi:10.1038/eye.2008.225
33. Foo LL, Lanca C, Wong CW, et al. Cost of Myopia Correction: A Systematic Review. *Front Med (Lausanne)*. 2021;8. doi:10.3389/fmed.2021.718724
34. Sankaridurg P, Tahhan N, Kandel H, et al. IMI Impact of Myopia. *Investigative Ophthalmology & Visual Science*. 2021;62(5):2. doi:10.1167/iovs.62.5.2
35. Rose K. Quality of life in myopia. *British Journal of Ophthalmology*. 2000;84(9):1031-1034. doi:10.1136/bjo.84.9.1031
36. Rose KA. Myopia, Lifestyle, and Schooling in Students of Chinese Ethnicity in Singapore and Sydney. *Archives of Ophthalmology*. 2008;126(4):527. doi:10.1001/archophth.126.4.527
37. French AN, Morgan IG, Mitchell P, Rose KA. Risk Factors for Incident Myopia in Australian Schoolchildren. *Ophthalmology*. 2013;120(10):2100-2108. doi:10.1016/j.ophtha.2013.02.035
38. Mutti DO, Hayes JR, Mitchell GL, et al. Refractive Error, Axial Length, and Relative Peripheral Refractive Error before and after the Onset of Myopia. *Investigative Ophthalmology & Visual Science*. 2007;48(6):2510. doi:10.1167/iovs.06-0562
39. He M, Zheng Y, Xiang F. Prevalence of Myopia in Urban and Rural Children in Mainland China. *Optometry and Vision Science*. 2009;86(1):40-44. doi:10.1097/OPX.0b013e3181940719
40. Gwiazda J, Hyman L, Dong LM, et al. Factors Associated with High Myopia After 7 Years of Follow-up in the Correction of Myopia Evaluation Trial (COMET) Cohort. *Ophthalmic Epidemiol*. 2007;14(4):230-237. doi:10.1080/01658100701486459
41. PACELLA R, MCLELLAN J, GRICE K, DEL BONO EA, WIGGS JL, GWIAZDA JE. Role of Genetic Factors in the Etiology of Juvenile-Onset Myopia Based on a Longitudinal Study of Refractive Error. *Optometry and Vision Science*. 1999;76(6):381-386. doi:10.1097/00006324-199906000-00017
42. MEW-MAY WU M, EDWARDS MH. The Effect of Having Myopic Parents: An Analysis of Myopia in Three Generations. *Optometry and Vision Science*. 1999;76(6):387-392. doi:10.1097/00006324-199906000-00018

43. Lipschutz H. MYOPIA AND NEARWORK. *British Journal of Ophthalmology*. 1935;19(11):611-612. doi:10.1136/bjo.19.11.611
44. Saw SM. How blinding is pathological myopia? *British Journal of Ophthalmology*. 2006;90(5):525-526. doi:10.1136/bjo.2005.087999
45. Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The Complications of Myopia: A Review and Meta-Analysis. *Investigative Ophthalmology & Visual Science*. 2020;61(4):49. doi:10.1167/iovs.61.4.49
46. Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RRA, Flitcroft DI. The Risks and Benefits of Myopia Control. *Ophthalmology*. 2021;128(11):1561-1579. doi:10.1016/j.ophtha.2021.04.032
47. Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. *Prog Retin Eye Res*. 2021;83:100923. doi:10.1016/j.preteyeres.2020.100923
48. Wolffsohn JS, Calossi A, Cho P, et al. Global trends in myopia management attitudes and strategies in clinical practice – 2019 Update. *Contact Lens and Anterior Eye*. 2020;43(1):9-17. doi:10.1016/j.clae.2019.11.002
49. Wolffsohn JS, Calossi A, Cho P, et al. Global trends in myopia management attitudes and strategies in clinical practice. *Contact Lens and Anterior Eye*. 2016;39(2):106-116. doi:10.1016/j.clae.2016.02.005
50. Leshno A, Farzavandi SK, Gomez-de-Liaño R, Sprunger DT, Wagnanski-Jaffe T, Mezer E. Practice patterns to decrease myopia progression differ among paediatric ophthalmologists around the world. *British Journal of Ophthalmology*. 2020;104(4):535-540. doi:10.1136/bjophthalmol-2019-314752
51. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. *The Lancet*. 2012;379(9827):1739-1748. doi:10.1016/S0140-6736(12)60272-4
52. Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan¹¹The authors have no proprietary interest in any aspect of the study. *Ophthalmology*. 2004;111(1):62-69. doi:10.1016/j.ophtha.2003.05.011
53. Xu L, Wang Y, Li Y, et al. Causes of Blindness and Visual Impairment in Urban and Rural Areas in Beijing. *Ophthalmology*. 2006;113(7):1134.e1-1134.e11. doi:10.1016/j.ophtha.2006.01.035
54. Resnikoff S, Pararajasegaram R. Blindness prevention programmes: past, present, and future. *Bull World Health Organ*. 2001;79(3):222-226.
55. Takashima T, Yokoyama T, Futagami S, et al. [The quality of life in patients with pathologic myopia]. *Nippon Ganka Gakkai Zasshi*. 2002;106(7):383-391.
56. Yokoi T, Moriyama M, Hayashi K, et al. Predictive factors for comorbid psychiatric disorders and their impact on vision-related quality of life in patients with high myopia. *Int Ophthalmol*. 2014;34(2):171-183. doi:10.1007/s10792-013-9805-8
57. World report on vision. Accessed April 7, 2022. <https://www.who.int/publications/item/9789241516570>
58. Gifford KL. Childhood and lifetime risk comparison of myopia control with contact lenses. *Contact Lens and Anterior Eye*. 2020;43(1):26-32. doi:10.1016/j.clae.2019.11.007
59. Huang J, Wen D, Wang Q, et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children. *Ophthalmology*. 2016;123(4):697-708. doi:10.1016/j.ophtha.2015.11.010
60. Smith EL. Optical treatment strategies to slow myopia progression: Effects of the visual extent of the optical treatment zone. *Exp Eye Res*. 2013;114:77-88. doi:10.1016/j.exer.2012.11.019
61. Wen D, Huang J, Chen H, et al. Efficacy and Acceptability of Orthokeratology for Slowing Myopic Progression in Children: A Systematic Review and Meta-Analysis. *J Ophthalmol*. 2015;2015:1-12. doi:10.1155/2015/360806
62. Li S, Kang M, Wu S, et al. Studies using concentric ring bifocal and peripheral add multifocal contact lenses to slow myopia progression in school-aged children: a meta-analysis. *Ophthalmic and Physiological Optics*. 2017;37(1):51-59. doi:10.1111/opo.12332
63. Payor RE, Woods J, Fonn D, et al. Feasibility Testing of a Novel Soft Contact Lens Optical Design to Reduce Suspected Risk Factors for the Progression of Juvenile Onset Myopia. Poster presented at ARVO annual meeting. *Invest Ophthalmol Vis Sci*. 2014;55(13):3638-3638.
64. Patents Awarded - Multifocal ophthalmic lens with induced aperture. Accessed September 2, 2025. <https://patents.google.com/patent/EP1381908B1/en>

65. Newman Steve. Tisilfocon A The Evidence to Support Permeability of 180+ - mivision. December 1, 2023. Accessed September 1, 2025. <https://mivision.com.au/2023/12/tisilfocon-a-the-evidence-to-support-permeability-of-180/>
66. Ladage PM, Yamamoto K, Ren DH, et al. Effects of rigid and soft contact lens daily wear on corneal epithelium, tear lactate dehydrogenase, and bacterial binding to exfoliated epithelial cells. *Ophthalmology*. 2001;108(7):1279-1288. doi:10.1016/S0161-6420(01)00639-X
67. Morgan PB, Maldonado-Codina C, Efron N. Comfort Response to Rigid and Soft Hyper-Transmissible Contact Lenses Used for Continuous Wear. *Eye & Contact Lens: Science & Clinical Practice*. Published online January 2003:S127-S130. doi:10.1097/00140068-200301001-00034
68. MALDONADO-CODINA C, MORGAN PB, EFRON N, EFRON S. Comparative Clinical Performance of Rigid versus Soft Hyper Dk Contact Lenses Used for Continuous Wear. *Optometry and Vision Science*. 2005;82(6):536-548. doi:10.1097/00006324-200506000-00018
69. MORGAN PB, EFRON N, MALDONADO-CODINA C, EFRON S. Adverse Events and Discontinuations With Rigid and Soft Hyper Dk Contact Lenses Used for Continuous Wear. *Optometry and Vision Science*. 2005;82(6):528-535. doi:10.1097/01.opx.0000168588.63897.0f
70. Albright RA, Venuti BD, Ichijima H, Nyunt AK, Cavanagh HD. Postmarket Surveillance of Menicon Z Rigid Gas-Permeable Contact Lenses for up to 30 Days Continuous Wear in the United States. *Eye & Contact Lens: Science & Clinical Practice*. 2010;36(5):241-244. doi:10.1097/ICL.0b013e3181efa61b
71. Woods C. Planned rigid lens replacement. In: Efron N, ed. *Contact Lens Practice*. 3rd Edition. Elsevier; 2017:187-192.
72. Swarbrick HA. Orthokeratology review and update. *Clin Exp Optom*. 2006;89(3):124-143. doi:10.1111/j.1444-0938.2006.00044.x
73. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R, Suzaki A. Short- and Long-Term Changes in Corneal Aberrations and Axial Length Induced by Orthokeratology in Children Are Not Correlated. *Eye & Contact Lens: Science & Clinical Practice*. 2017;43(6):358-363. doi:10.1097/ICL.0000000000000290
74. Lau JK, Vincent SJ, Cheung S, Cho P. The influence of orthokeratology compression factor on ocular higher-order aberrations. *Clin Exp Optom*. 2020;103(1):123-128. doi:10.1111/cxo.12933
75. Lau JK, Vincent SJ, Cheung SW, Cho P. Higher-Order Aberrations and Axial Elongation in Myopic Children Treated With Orthokeratology. *Investigative Ophthalmology & Visual Science*. 2020;61(2):22. doi:10.1167/iavs.61.2.22
76. Cho P, Cheung SW. Retardation of Myopia in Orthokeratology (ROMIO) Study: A 2-Year Randomized Clinical Trial. *Investigative Ophthalmology & Visual Science*. 2012;53(11):7077. doi:10.1167/iavs.12-10565
77. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Myopia Control with Orthokeratology Contact Lenses in Spain: Refractive and Biometric Changes. *Investigative Ophthalmology & Visual Science*. 2012;53(8):5060. doi:10.1167/iavs.11-8005
78. Chen C, Cheung SW, Cho P. Myopia Control Using Toric Orthokeratology (TO-SEE Study). *Investigative Ophthalmology & Visual Science*. 2013;54(10):6510. doi:10.1167/iavs.13-12527
79. Boost M, Cho P, Lai S. Efficacy of multipurpose solutions for rigid gas permeable lenses. *Ophthalmic and Physiological Optics*. 2006;26(5):468-475. doi:10.1111/j.1475-1313.2006.00398.x
80. Choy CKM, Cho P, Boost M V. Cytotoxicity of rigid gas-permeable lens care solutions. *Clin Exp Optom*. 2013;96(5):467-471. doi:10.1111/cxo.12039
81. Shi G sen, Boost M V, Cho P. Does the presence of QAC genes in staphylococci affect the efficacy of disinfecting solutions used by orthokeratology lens wearers? *British Journal of Ophthalmology*. 2016;100(5):708-712. doi:10.1136/bjophthalmol-2015-307811
82. Hiraoka T, Yoshimitsu M, Santodomingo-Rubido J, Kondo H, Oshika T. A novel quantitative evaluation of deposits adhered to worn orthokeratology contact lenses. *Jpn J Ophthalmol*. 2021;65(6):855-863. doi:10.1007/s10384-021-00873-1
83. Cooper J, O'Connor B, Watanabe R, et al. Case Series Analysis of Myopic Progression Control With a Unique Extended Depth of Focus Multifocal Contact Lens. *Eye & Contact Lens: Science & Clinical Practice*. 2018;44(5):e16-e24. doi:10.1097/ICL.0000000000000440

84. New Clinical Evidence through 6 Years. Menicon Data on File.; 2021.
85. Miller J, Long B, Dillehay S. Children's evaluation of a unique myopia progression control lens design. Poster presented at annual meeting of American Academy of Optometry; 2021.
86. Tuan K mon A. A Randomized Controlled Trial for Myopia Progression Control Using Catenary Power Profile Contact Lenses: 12-month Effectiveness and Safety. Poster presented at ARVO annual meeting. Invest Ophthalmol Vis Sci. 2024;65(7):2697-2697.
87. Cooper J, Aller T, Smith EL, Chan K, Dillehay SM, O'Connor B. Retrospective Analysis of a Clinical Algorithm for Managing Childhood Myopia Progression. Optometry and Vision Science. 2023;100(1):117-124. doi:10.1097/OPX.0000000000001978
88. Lederman C. Myopia control with extended depth of focus multifocal contact lenses. Poster presented at American Association for Pediatric Ophthalmology and Strabismus (AAPOS); 2023; New York, USA.
89. Walline JJ, Walker MK, Mutti DO, et al. Effect of High Add Power, Medium Add Power, or Single-Vision Contact Lenses on Myopia Progression in Children. JAMA. 2020;324(6):571. doi:10.1001/jama.2020.10834
90. Tuan KA, Dillehay SM, the PROTECT Study Group. Learnings of Managing Myopic Children Using Catenary Power Profile Multifocal Soft Contact Lenses from the PROTECT Randomized Clinical Trial. Poster presented at Global Specialty Lens Symposium; January 17, 2025; Las Vegas, NV, USA.
91. Carracedo G, Privado-Aroco A, Tuan A. Evaluation of Visual Acuity With Multifocal Catenary Curve-Based Contact Lens Design in Different Degrees of Astigmatism. Poster presented at Global Specialty Lens Symposium; January 16, 2025; Las Vegas, NV, USA.
92. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R, Sugimoto K. Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia. Curr Eye Res. 2017;42(5):713-720. doi:10.1080/02713683.2016.1221979
93. Bullimore MA, Sinnott LT, Jones-Jordan LA. The Risk of Microbial Keratitis With Overnight Corneal Reshaping Lenses. Optometry and Vision Science. 2013;90(9):937-944. doi:10.1097/OPX.0b013e31829cac92
94. Li SM, Kang MT, Wu SS, et al. Efficacy, Safety and Acceptability of Orthokeratology on Slowing Axial Elongation in Myopic Children by Meta-Analysis. Curr Eye Res. 2016;41(5):600-608. doi:10.3109/02713683.2015.1050743
95. Liu YM, Xie P. The Safety of Orthokeratology—A Systematic Review. Eye & Contact Lens: Science & Clinical Practice. 2016;42(1):35-42. doi:10.1097/ICL.0000000000000219
96. Bullimore MA. The Safety of Soft Contact Lenses in Children. Optometry and Vision Science. 2017;94(6):638-646. doi:10.1097/OPX.0000000000001078
97. Cheng X, Brennan NA, Toubouti Y, Greenaway NL. Safety of soft contact lenses in children: retrospective review of six randomized controlled trials of myopia control. Acta Ophthalmol. 2020;98(3). doi:10.1111/aos.14283
98. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Orthokeratology vs. Spectacles. Optometry and Vision Science. 2012;89(8):1133-1139. doi:10.1097/OPX.0b013e318263c5af
99. Clinical Evaluation Report for Menicon Z Night Orthokeratology Contact Lenses. Menicon Data on File.; 2017.
100. PERRIGIN J, PERRIGIN D, QUINTERO S, GROSVENOR T. Silicone-Acrylate Contact Lenses for Myopia Control: 3-Year Results. Optometry and Vision Science. 1990;67(10):764-769. doi:10.1097/00006324-199010000-00003
101. Katz J, Schein OD, Levy B, et al. A randomized trial of rigid gas permeable contact lenses to reduce progression of children's myopia. Am J Ophthalmol. 2003;136(1):82-90. doi:10.1016/S0002-9394(03)00106-5
102. Walline JJ, Gaume A, Jones LA, et al. Benefits of Contact Lens Wear for Children and Teens. Eye & Contact Lens: Science & Clinical Practice. 2007;33(6):317-321. doi:10.1097/ICL.0b013e31804f80fb
103. Lipson MJ. Long-term Clinical Outcomes for Overnight Corneal Reshaping in Children and Adults. Eye & Contact Lens: Science & Clinical Practice. 2008;34(2):94-99. doi:10.1097/ICL.0b013e31811eba10

104. Walline JJ, Jones LA, Sinnott L, et al. Randomized Trial of the Effect of Contact Lens Wear on Self-Perception in Children. *Optometry and Vision Science*. 2009;86(3):222-232. doi:10.1097/OPX.0b013e3181971985
105. Jones-jordan LA, Chitkara M, Coffey B, et al. A comparison of spectacle and contact lens wearing times in the ACHIEVE study. *Clin Exp Optom*. 2010;93(3):157-163. doi:10.1111/j.1444-0938.2010.00480.x
106. Rah MJ, Walline JJ, Jones-Jordan LA, et al. Vision Specific Quality of Life of Pediatric Contact Lens Wearers. *Optometry and Vision Science*. 2010;87(8):560-566. doi:10.1097/OPX.0b013e3181e6a1c8
107. Walline JJ, Jones LA, Sinnott LT. Corneal reshaping and myopia progression. *British Journal of Ophthalmology*. 2009;93(9):1181-1185. doi:10.1136/bjo.2008.151365
108. Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-Term Effect of Overnight Orthokeratology on Axial Length Elongation in Childhood Myopia: A 5-Year Follow-Up Study. *Investigative Ophthalmology & Visual Science*. 2012;53(7):3913. doi:10.1167/iovs.11-8453
109. Downie LE, Lowe R. Corneal Reshaping Influences Myopic Prescription Stability (CRIMPS). *Eye & Contact Lens: Science & Clinical Practice*. 2013;39(4):303-310. doi:10.1097/ICL.0b013e318298ee76
110. Hiraoka T, Kakita T, Okamoto F, Oshika T. Influence of Ocular Wavefront Aberrations on Axial Length Elongation in Myopic Children Treated with Overnight Orthokeratology. *Ophthalmology*. 2015;122(1):93-100. doi:10.1016/j.ophtha.2014.07.042
111. Lee YC, Wang JH, Chiu CJ. Effect of Orthokeratology on myopia progression: twelve-year results of a retrospective cohort study. *BMC Ophthalmol*. 2017;17(1):243. doi:10.1186/s12886-017-0639-4
112. Hiraoka T, Sekine Y, Okamoto F, Mihashi T, Oshika T. Safety and efficacy following 10 years of overnight orthokeratology for myopia control. *Ophthalmic and Physiological Optics*. 2018;38(3):281-289. doi:10.1111/opo.12460
113. Efron N, Morgan PB, Woods CA. Survey of Contact Lens Prescribing to Infants, Children, and Teenagers. *Optometry and Vision Science*. 2011;88(4):461-468. doi:10.1097/OPX.0b013e31820efa0f
114. Efron N, Morgan PB, Woods CA, Santodomingo-Rubido J, Nichols JJ. International survey of contact lens fitting for myopia control in children. *Contact Lens and Anterior Eye*. 2020;43(1):4-8. doi:10.1016/j.clae.2019.06.008
115. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Myopia Control With Orthokeratology Contact Lenses in Spain. *Eye & Contact Lens: Science & Clinical Practice*. 2013;39(2):153-157. doi:10.1097/ICL.0b013e31827a0241
116. Mutti DO, Sinnott LT, Mitchell GL, et al. Relative Peripheral Refractive Error and the Risk of Onset and Progression of Myopia in Children. *Investigative Ophthalmology & Visual Science*. 2011;52(1):199. doi:10.1167/iovs.09-4826
117. Zadnik K, Sinnott LT, Cotter SA, et al. Prediction of Juvenile-Onset Myopia. *JAMA Ophthalmol*. 2015;133(6):683. doi:10.1001/jamaophthalmol.2015.0471
118. Donovan L, Sankaridurg P, Ho A, Naduvilath T, Smith EL, A. Holden B. Myopia Progression Rates in Urban Children Wearing Single-Vision Spectacles. *Optometry and Vision Science*. 2012;89(1):27-32. doi:10.1097/OPX.0b013e3182357f79
119. Cho P, Cheung SW. Discontinuation of orthokeratology on eyeball elongation (DOEE). *Contact Lens and Anterior Eye*. 2017;40(2):82-87. doi:10.1016/j.clae.2016.12.002
120. Clinical Evaluation Report for Menicon Z Night Orthokeratology Contact Lenses. Menicon Data on File.; 2015.
121. Chan KY, Cheung SW, Cho P. Clinical performance of an orthokeratology lens fitted with the aid of a computer software in Chinese children. *Contact Lens and Anterior Eye*. 2012;35(4):180-184. doi:10.1016/j.clae.2012.01.004
122. Wittich CM, Burkle CM, Lanier WL. Ten Common Questions (and Their Answers) About Off-label Drug Use. *Mayo Clin Proc*. 2012;87(10):982-990. doi:10.1016/j.mayocp.2012.04.017

123. Aronson JK, Ferner RE. Unlicensed and off-label uses of medicines: definitions and clarification of terminology. *Br J Clin Pharmacol*. 2017;83(12):2615-2625. doi:10.1111/bcp.13394
124. Riley JB, Basilius PA. Physicians' liability for off-label prescriptions. *Nephrol News Issues*. 2007;21(7):43-44, 46-47.
125. Wilkes M, Johns M. Informed Consent and Shared Decision-Making: A Requirement to Disclose to Patients Off-Label Prescriptions. *PLoS Med*. 2008;5(11):e223. doi:10.1371/journal.pmed.0050223
126. Lenk C, Koch P, Zappel H, Wiesemann C. Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics. *Eur J Pediatr*. 2009;168(12):1473-1478. doi:10.1007/s00431-009-0956-6
127. Lenk C, Duttge G. Ethical and legal framework and regulation for off-label use: European perspective. *Ther Clin Risk Manag*. Published online July 2014:537. doi:10.2147/TCRM.S40232
128. Drenska M, Getov I. Research on Approaches for Regulation of the "Off-label" use of Medicinal Products in the European Union. *Acta Medica Bulgarica*. 2017;44(1):17-21. doi:10.1515/amb-2017-0003
129. Santodomingo-Rubido J, Cheung SW, Villa-Collar C; ROMIO/MCOS/TO-SEE Groups. A new look at the myopia control efficacy of orthokeratology. *Cont Lens Anterior Eye*. 2024 ;47(5):102251. doi: 10.1016/j.clae.2024.102251
130. Santodomingo-Rubido J, Cheung SW, Villa-Collar C; ROMIO/MCOS/TO-SEE Groups. The safety of orthokeratology contact lens wear in slowing the axial elongation of the eye in children. *Cont Lens Anterior Eye*. 2024:102258. doi: 10.1016/j.clae.2024.102258.

